Catalog No.
YHF05601
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Val485-Trp743
Predicted molecular weight
31.81 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P54802
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
NAGLU, Alpha-N-acetylglucosaminidase, N-acetyl-alpha-glucosaminidase, UFHSD1, NAG
Association of certain biochemical parameters related to bone cycle with genotype in MPS IIIB patients., PMID:40104299
An augmented transformer model trained on protein family specific variant data leads to improved prediction of variants of uncertain significance., PMID:39869148
Multi-omics analyses of early-onset familial Alzheimer's disease and Sanfilippo syndrome zebrafish models reveal commonalities in disease mechanisms., PMID:39798820
A Drosophila model of mucopolysaccharidosis IIIB., PMID:39737777
Haploinsufficiency of lysosomal enzyme genes in Alzheimer's disease., PMID:39605615
Identification of Orthosteric and Allosteric Pharmacological Chaperones for Mucopolysaccharidosis Type IIIB., PMID:38830828
Genetic features of patients with MPS type IIIB: Description of five pathogenic gene variations., PMID:38492611
A Proteomic Investigation to Discover Candidate Proteins Involved in Novel Mechanisms of 5-Fluorouracil Resistance in Colorectal Cancer., PMID:38391955
Explore the role of long noncoding RNAs and mRNAs in intracranial atherosclerotic stenosis: From the perspective of neutrophils., PMID:38284107
Metabolic Cardiomyopathies and Cardiac Defects in Inherited Disorders of Carbohydrate Metabolism: A Systematic Review., PMID:37239976
Urinary complement proteins in IgA nephropathy progression from a relative quantitative proteomic analysis., PMID:37065697
Safety, pharmacokinetics and CNS distribution of tralesinidase alfa administered via intracerebroventricular infusion to juvenile cynomolgus monkeys., PMID:36923444
Mucopolysaccharidosis type III (subtype IIIB) diagnosis as a spectrum disorder: A case report from Kosovo., PMID:36855989
dNAGLU Extends Life Span and Promotes Fitness and Stress Resistance in Drosophila., PMID:36430913
Disease correction in mucopolysaccharidosis type IIIB mice by intraparenchymal or cisternal delivery of a capsid modified AAV8 codon-optimized NAGLU vector., PMID:35997776
Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIB., PMID:35717448
Highly diverse phenotypes of mucopolysaccharidosis type IIIB sibling patients: effects of an additional mutation in the AUTS2 gene., PMID:35525889
Downregulation of NAGLU in VEC Increases Abnormal Accumulation of Lysosomes and Represents a Predictive Biomarker in Early Atherosclerosis., PMID:35155448
Cell-Mediated Immunity to NAGLU Transgene Following Intracerebral Gene Therapy in Children With Mucopolysaccharidosis Type IIIB Syndrome., PMID:34040605
Evaluation of artificial signal peptides for secretion of two lysosomal enzymes in CHO cells., PMID:34032266
Biochemical evaluation of intracerebroventricular rhNAGLU-IGF2 enzyme replacement therapy in neonatal mice with Sanfilippo B syndrome., PMID:33839004
Gene expression in the striatum of cynomolgus monkeys after chronic administration of cocaine and heroin., PMID:33404192
Coinheritance of novel mutations in NAGLU causing mucopolysaccharidosis type IIIB and in DDHD2 causing spastic paraplegia54 in a Turkish family., PMID:33246910
Proteomic Analysis of Mucopolysaccharidosis IIIB Mouse Brain., PMID:32111039
High-Salt Loading Downregulates Nrf2 Expression in a Sodium-Dependent Manner in Renal Collecting Duct Cells., PMID:32038274
Translational studies of intravenous and intracerebroventricular routes of administration for CNS cellular biodistribution for BMN 250, an enzyme replacement therapy for the treatment of Sanfilippo type B., PMID:31942701
A Novel Pathogenic Variant in NAGLU (N-Acetyl-Alpha-Glucosaminidase) gene Identified by Targeted Next-Generation Sequencing Followed by in Silico Analysis., PMID:31645877
Assessment of predicted enzymatic activity of α-N-acetylglucosaminidase variants of unknown significance for CAGI 2016., PMID:31342580
Differential Uptake of NAGLU-IGF2 and Unmodified NAGLU in Cellular Models of Sanfilippo Syndrome Type B., PMID:31309128
PLA2G4A/cPLA2-mediated lysosomal membrane damage leads to inhibition of autophagy and neurodegeneration after brain trauma., PMID:31238788
Biochemical, machine learning and molecular approaches for the differential diagnosis of Mucopolysaccharidoses., PMID:30903511
Structural characterization of the α-N-acetylglucosaminidase, a key enzyme in the pathogenesis of Sanfilippo syndrome B., PMID:30802506
BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis., PMID:30657762
Final results of the phase 1/2, open-label clinical study of intravenous recombinant human N-acetyl-α-d-glucosaminidase (SBC-103) in children with mucopolysaccharidosis IIIB., PMID:30635159
Vitamin D3 activates the autolysosomal degradation function against Helicobacter pylori through the PDIA3 receptor in gastric epithelial cells., PMID:30612517
A novel frameshift deletion in NAGLU causing sanfilipo type III-B in an Indian family., PMID:30564336
Generation of two induced pluripotent stem cells lines from a Mucopolysaccharydosis IIIB (MPSIIIB) patient., PMID:30408744
A mechanism-based GlcNAc-inspired cyclophellitol inactivator of the peptidoglycan recycling enzyme NagZ reverses resistance to β-lactams in Pseudomonas aeruginosa., PMID:30178799
A novel mutation in SGSH causing Sanfillipo type 3A Mucopolysaccharidoses in an Indian family., PMID:30023302
Utilizing ExAC to assess the hidden contribution of variants of unknown significance to Sanfilippo Type B incidence., PMID:29979746
Integrative analysis of oncogenic fusion genes and their functional impact in colorectal cancer., PMID:29955133
Trehalose reduces retinal degeneration, neuroinflammation and storage burden caused by a lysosomal hydrolase deficiency., PMID:29916295
Mucopolysaccharidosis IIIB and mild skeletal anomalies: coexistence of NAGLU and CYP26B1 missense variations in the same patient in a Chinese family., PMID:29606097
EGFR activation triggers cellular hypertrophy and lysosomal disease in NAGLU-depleted cardiomyoblasts, mimicking the hallmarks of mucopolysaccharidosis IIIB., PMID:29348482
Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy., PMID:29186350
Myocardial Injury Is Distinguished from Stable Angina by a Set of Candidate Plasma Biomarkers Identified Using iTRAQ/MRM-Based Approach., PMID:29068691
High-Throughput Screen Fails to Identify Compounds That Enhance Residual Enzyme Activity of Mutant N-Acetyl-α-Glucosaminidase in Mucopolysaccharidosis Type IIIB., PMID:28836185
Processing of mutant N-acetyl-α-glucosaminidase in mucopolysaccharidosis type IIIB fibroblasts cultured at low temperature., PMID:28751108
Blind prediction of deleterious amino acid variations with SNPs&GO., PMID:28102005
Lysosomal Proteins as a Therapeutic Target in Neurodegeneration., PMID:28099085
For research use only. Not for human or drug use.
